Clover Health Investments (CLOV) Faces A Valuation Test Ahead Of August Earnings
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Clover Health Investments (CLOV) has scheduled its second quarter 2026 earnings release for August 5, 2026, after the market closes. Management will host a webcast to discuss the results and business performance.
See our latest analysis for Clover Health Investments.
Clover Health Investments’ recent share price pullback, with a 7 day share price return of down 15.59% and a 1 day move of down 5.13%, comes after a strong 90 day share price return of 130.05% and 1 year total shareholder return of 52.05%. This suggests momentum has cooled ahead of the earnings update and following planned insider selling under a trading plan.
If you are weighing what else to watch in healthcare as earnings approach, this could be a useful time to scan 41 healthcare AI stocks
For Clover Health Investments, the sharp swing from a strong 90 day run to a recent pullback can signal either a reassessment of the business or a quick shift in sentiment, which makes the next question valuation.
Most Popular Narrative: 7% Overvalued
Clover Health Investments last closed at $4.44, while the most followed narrative places fair value at $4.15, suggesting the share price is running ahead of that framework.
The analysts have a consensus price target of $4.15 for Clover Health Investments based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $4.75, and the most bearish reporting a price target of just $3.5.
Want to know what has to happen for that fair value to stack up? The narrative leans on rapid revenue compounding, margin improvement and a rich future earnings multiple. Curious which specific profit and growth assumptions sit underneath those headlines? The full story lays out the numbers in black and white.
Result: Fair Value of $4.15 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there are clear pressure points for Clover Health Investments, including higher medical and pharmacy utilization and ongoing GAAP net losses, which keep its path to sustained profitability uncertain.
Find out about the key risks to this Clover Health Investments narrative.
Another View on Clover Health Investments’ Valuation
The analyst narrative frames Clover Health Investments as about 7% overvalued at $4.44 versus a fair value of $4.15. Yet on a simple P/S basis of 1.1x, the stock looks cheap relative to peers at 2.3x and a fair ratio of 1.3x, which points to a valuation gap investors need to interpret carefully.
